Therapeutic Approaches and Targets for Viral Infections

A cutting-edge technique for effectively enhancing humoral and cellular immune responses to protein antigens is DNA immunisation. Either inactivated viruses or constricted viruses are present in viral vaccines. In order to elicit a response, inactive viral vaccines must contain more antigen than live immunisations. They contain viruses that can no longer replicate. A clinically proven effective treatment option, allergy immunotherapy may significantly lessen the patient's allergic symptoms and the need for conventional, symptom-relieving medication. A particular class of medication used to treat viral infections is known as an antiviral drug.

  • Antiviral Medicines

  • Oseltamivir phosphate, also known as Tamiflu® or its generic equivalent,

  • (Trade name: Relenza®) zanamivir

  • peramivir, also known as Rapivab®.

  • Xofluza® (trade name for baloxavir marboxil).

    Related Conference of Therapeutic Approaches and Targets for Viral Infections

    November 21-22, 2024

    7th Pathology and Infectious Disease Conference

    Dubai, UAE
    November 28-29, 2024

    20th World Congress on Infection Prevention and Control

    Paris, France
    March 13-14, 2025

    9th International Conference on Rare Diseases

    Prague, Czech Republic
    March 17-18, 2025

    12th International Congress on Infectious Diseases

    Berlin, Germany
    April 14-15, 2025

    15th European Epidemiology and Public Health Congress

    Budapest, Hungary
    June 02-03, 2025

    14th World Congress on Rare Diseases and Orphan Drugs

    Amsterdam, Netherlands
    June 02-03, 2025

    17th Euro-Global Conference on Infectious Diseases

    Amsterdam, Netherlands

    Therapeutic Approaches and Targets for Viral Infections Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in